Potensi RAG-01 Ractigen dalam Pengobatan Kanker Kandung Kemih Non-invasif
Ractigen’s RAG-01, a small activating RNA therapy for non-muscle invasive bladder cancer, shows a 66.7% complete response rate in early Phase I trial results. The therapy targets the p21 tumor …
Potensi RAG-01 Ractigen dalam Pengobatan Kanker Kandung Kemih Non-invasif Read More